System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Ppublish 77 citations

PubMed: 34058573 DOI: 10.1016/j.reprotox.2021.05.007

Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine.

Reprod Toxicol 103:28-35

Authors: Christopher J Bowman, Marie Bouressam, Sarah N Campion, Gregg D Cappon, Natasha R Catlin, Mark W Cutler, Jan Diekmann, Cynthia M Rohde, Rani S Sellers, Claudia Lindemann

Affiliations

  • Drug Safety Research and Development, Pfizer Worldwide Research, Development & Medical, Groton, CT, USA.
  • Charles River Laboratories France Safety Assessmsent SAS, Lyon, France.
  • Drug Safety Research and Development, Pfizer Worldwide Research, Development & Medical, Groton, CT, USA.
  • Vaccine Research and Development, Pfizer Worldwide Research, Development & Medical, Pearl River, NY, USA.
  • Non-Clinical Safety, BioNTech SE, Mainz, Germany.
  • Drug Safety Research and Development, Pfizer Worldwide Research, Development & Medical, Pearl River, NY, USA.

Abstract

BNT162b2 is a vaccine developed to prevent coronavirus disease 2019 (COVID-19). BNT162b2 is a lipid nanoparticle formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein locked in its prefusion conformation. A developmental and reproductive toxicity study was conducted in rats according to international regulatory guidelines. The full human BNT162b2 dose of 30 μg mRNA/dose (>300 times the human dose on a mg/kg basis) was administered intramuscularly to 44 female rats 21 and 14 days prior to mating and on gestation days 9 and 20. Half of the rats were subject to cesarean section and full fetal examination at the end of gestation, and the other half were allowed to deliver and were monitored to the end of lactation. A robust neutralizing antibody response was confirmed prior to mating and at the end of gestation and lactation. The presence of neutralizing antibodies was also confirmed in fetuses and offspring. Nonadverse effects, related to the local injection site reaction, were noted in dams as expected from other animal studies and consistent with observations in humans. There were no effects of BNT162b2 on female mating performance, fertility, or any ovarian or uterine parameters nor on embryo-fetal or postnatal survival, growth, physical development or neurofunctional development in the offspring through the end of lactation. Together with the safety profile in nonpregnant people, this ICH-compliant nonclinical safety data supports study of BNT162b2 in women of childbearing potential and pregnant and lactating women.

MeSH

Coronavirus, Pregnancy, Lactation, Sars-Cov-2, Fertility, Safety, Vaccines, Covid-19 Vaccines, Rna, Messenger, Antibodies, Neutralizing, Covid-19, Toxicology

Cited by